Diabetic macular edema (DME) is a major cause of blindness worldwide. The current standard of care includes laser treatments and regular intraocular injections of repurposed anticancer drugs. In our kallikrein program, we are pursuing a promising alternate pathway to target DME, the kallikrein-kinin system. Using Verseon’s proprietary, computer-driven drug discovery platform, we have developed multiple chemotypes of potent, selective plasma kallikrein inhibitors that allow for more convenient administration as eye drops. Verseon’s compounds demonstrate good permeability into the eye in in vivo studies and readily achieve therapeutic levels in the back of the eye. Furthermore, some of Verseon’s candidates show excellent systemic pharmacokinetics and good oral bioavailability, which also allows for their development as novel oral therapeutics.
Session ID: 26012